# Veeva Systems (VEEV) - Recent Events ## Filings that contain financial statements Veeva furnishes its quarterly results as an Exhibit 99.1 press release to a Form 8-K (Item 2.02). Each release includes condensed consolidated financial statements. - Form 8-K filed August 26, 2026, accession 0001393052-26-000032: second quarter of fiscal 2027 (three and six months ended July 31, 2026). Holds the condensed consolidated balance sheet (July 31, 2026 and January 31, 2026), statements of comprehensive income (three and six months), cash flow statement (six months), and a GAAP to non-GAAP reconciliation. - Form 8-K filed June 3, 2026, accession 0001393052-26-000022: first quarter of fiscal 2027 (quarter ended April 30, 2026). Holds the balance sheet and income statement. - Form 8-K filed March 4, 2026, accession 0001393052-26-000007: fourth quarter and full fiscal year 2026 (year ended January 31, 2026). Holds the consolidated balance sheet and income statement. - Form 8-K filed November 20, 2025, accession 0001393052-25-000074: third quarter of fiscal 2026 (quarter ended October 31, 2025). - Form 8-K filed August 27, 2025, accession 0001393052-25-000063: second quarter of fiscal 2026 (quarter ended July 31, 2025). - Form 8-K filed May 28, 2025, accession 0001393052-25-000037: first quarter of fiscal 2026 (quarter ended April 30, 2025). ## Earnings and guidance **August 26, 2026 - Q2 fiscal 2027 results (accession 0001393052-26-000032).** Total revenues were $928.0 million, up 18% from $789.1 million a year earlier; subscription revenues were $766.8 million, up 16%. Operating income was $275.0 million (up 40%) and non-GAAP operating income $415.9 million (up 18%). Net income was $273.4 million and diluted EPS $1.66 (non-GAAP $2.35). Management said results exceeded guidance on all metrics and that its full-year view improved across the board. - Guidance raised for fiscal 2027 (year ending January 31, 2027): total revenues of $3,682 to $3,687 million (previously $3,635 to $3,645 million), non-GAAP operating income of about $1,640 million (previously about $1,610 million), and non-GAAP diluted EPS of approximately $9.21 (previously approximately $9.05). - Third quarter guidance (quarter ending October 31, 2026): revenues of $932 to $935 million, non-GAAP operating income of $417 to $420 million, and non-GAAP diluted EPS of $2.33 to $2.34. - Highlights cited: more than 180 Vault CRM customers live, with total top 20 biopharma commitments to Vault CRM reaching 12 globally; Veeva Falcon (agentic labor platform for clinical, regulatory and safety) has five early adopters and is on track for initial go-lives this year. **June 3, 2026 - Q1 fiscal 2027 results (accession 0001393052-26-000022).** Revenues were $882.9 million, up 16%; subscription revenues $730.2 million, up 15%. Non-GAAP operating income was $395.4 million and diluted EPS $1.57 (non-GAAP $2.24). Results exceeded guidance on all metrics and full-year guidance was raised from the March figures (revenues $3,585 to $3,600 million, non-GAAP operating income about $1,590 million, non-GAAP EPS about $8.85) to revenues of $3,635 to $3,645 million, non-GAAP operating income of about $1,610 million and non-GAAP EPS of approximately $9.05. **March 4, 2026 - Q4 and fiscal 2026 results (accession 0001393052-26-000007).** Fiscal 2026 total revenues were $3,195.3 million, up 16%; subscription revenues $2,684.2 million, up 17%. Operating income was $916.4 million (up 33%), net income $908.9 million and diluted EPS $5.44 (non-GAAP $8.10). Fourth quarter revenues were $836.0 million. Initial fiscal 2027 guidance: revenues of $3,585 to $3,600 million, non-GAAP operating income of about $1,590 million, non-GAAP EPS of approximately $8.85. The release restated the company's target of a $6 billion revenue run rate by 2030. Earlier results: Q3 fiscal 2026 on November 20, 2025 (accession 0001393052-25-000074), Q2 fiscal 2026 on August 27, 2025 (0001393052-25-000063) and Q1 fiscal 2026 on May 28, 2025 (0001393052-25-000037). ## Capital actions **January 5, 2026 - share repurchase program (accession 0001393052-26-000003).** The board authorized repurchases of up to $2 billion of Class A common stock, with a two-year term, via open market purchases, privately negotiated transactions or Rule 10b5-1 plans. It was the company's first repurchase program. The program does not obligate Veeva to buy any set number of shares and can be suspended at any time. Execution is reported in the Form 10-Q for the quarter ended July 31, 2026 (accession 0001393052-26-000036): the company repurchased 1,408,414 shares in the second quarter at an average of $174.48 (about $245.7 million) and 2,663,443 shares in the six months at an average of $175.28 (about $466.8 million), all in open market transactions. About $1.4 billion remained available at July 31, 2026. ## Acquisitions (both closed) - **Ostro (Rise Healthcare Tech, Inc.) - closed March 9, 2026.** The Form 10-Q for the quarter ended July 31, 2026 (accession 0001393052-26-000036) states Veeva "acquired all outstanding stock" of Rise Healthcare Tech, Inc. for total consideration of $90 million ($70 million net of cash acquired); goodwill of $44.4 million and purchased intangibles of $25.5 million were recorded. No separate Form 8-K was filed for the deal. The June 3, 2026 release (0001393052-26-000022) describes Ostro, an AI-driven conversational platform, as "acquired in March". - **Copli - closed in the second quarter of fiscal 2027 (May through July 2026).** The August 26, 2026 release (0001393052-26-000032) says the company "acquired Copli in the quarter." No price or terms are disclosed in the filings reviewed. ## Litigation and legal **August 13, 2025 (reported August 18, 2025) - IQVIA settlement (accession 0001393052-25-000058).** Veeva and IQVIA settled all litigation pending since 2017. Neither side pays damages and all claims and counterclaims are dismissed with prejudice. The parties also entered long-term commercial and clinical partnership and data-access agreements. Veeva stated it would make a one-time payment of approximately $31 million to law firms under previously disclosed outcome-based fee arrangements. ## Management and board changes - **August 20, 2026 (accession 0001213900-26-092096):** Dan Rizzo appointed EVP, Sales, Consulting, and Services, effective October 2, 2026. He succeeds Thomas D. Schwenger, President and Chief Customer Officer, who resigned on August 18, 2026 effective October 2, 2026 to become CEO of a long-standing Veeva partner. - **April 20, 2026 (accession 0001393052-26-000018):** Josh Faddis, Senior Vice President and General Counsel, intends to retire effective November 1, 2026 and move to a part-time advisor role; a successor will be appointed at that time. - **December 10, 2025 (accession 0001393052-25-000082):** Vipin Kondath, Corporate Controller since April 2022, appointed principal accounting officer effective December 12, 2025, following Chief Accounting Officer Kristine Diamond's resignation effective December 11, 2025 (announced November 18, 2025, accession 0001393052-25-000070). - **March 2025 (accession 0001393052-25-000010):** Director Tina Hunt informed the board of her intention to retire, effective immediately before the 2025 annual meeting. ## Annual meetings - **June 17, 2026 (accession 0001393052-26-000029):** All nine director nominees were elected. Matthew J. Wallach received the lowest support (about 84.2 million for, 47.9 million against), followed by Gordon Ritter (about 97.1 million for, 34.9 million against); Mark Carges received 105.5 million for and 26.5 million against. - **June 18, 2025 (accession 0001393052-25-000052):** Directors elected at the 2025 annual meeting. No debt issuance, dividend, stock split, impairment, restructuring or going-concern item appears in the 8-K filings from March 2025 through August 2026.